Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.43 |
| ▸ | IKZF3 | Q9UKT9 | 10/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27241633 | 0.89 | IKZF2 (0.53) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL29927258 | 0.88 | CRBN (0.51) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL20231931 | 0.88 | CRBN (0.51) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL27241671 | 0.86 | IKZF1 (0.46) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL25134262 | 0.84 | CRBN (0.44) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL29928133 | 0.84 | CRBN (0.44) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL31129674 | 0.84 | IKZF2 (0.48) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL31129681 | 0.83 | IKZF2 (0.49) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL29132187 | 0.83 | CRBN (0.43) | CRBNIKZF3IKZF2IKZF1DDB1 | |
| SCHEMBL25133969 | 0.83 | CRBN (0.43) | CRBNIKZF3IKZF2IKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605387-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024086759-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 47/4885IKZF3 43/4885IKZF2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.